• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Elevation Oncology Inc. (Amendment)

    2/14/24 4:00:25 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELEV alert in real time by email
    SC 13G/A 1 b111244sc13ga1.htm AMENDMENT NO. 1

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Elevation Oncology, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

     

    28623U101

    (CUSIP Number)

     

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 Pages 
      

     

    CUSIP No. 28623U101

     

    13G/A Page 2 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group* (a) ☐
    (
    b) ☒
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

    Number of
    Shares
    BENEFICIALLY
    Owned by
    Each Reporting
    Person with
    5

    Sole Voting Power

     

    0 

    6

    Shared Voting Power

     

    4,300,454

    7

    Sole Dispositive Power

     

    0 

    8

    Shared Dispositive Power

     

    4,300,454

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,300,454

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.99%

    12

    type of reporting person

     

    pN 

     

     Page 2 of 8 Pages 
      

     

    CUSIP No.  28623U101

     

    13G/A Page 3 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group* (a) ☐
    (
    b) ☒

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

    Number of
    Shares
    BENEFICIALLY
    Owned by
    Each Reporting
    Person with
    5

    Sole Voting Power

     

    0 

    6

    Shared Voting Power

     

    4,300,454

    7

    Sole Dispositive Power

     

    0 

    8

    Shared Dispositive Power

     

    4,300,454

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,300,454

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.99%

    12

    type of reporting person

     

    OO

     

     Page 3 of 8 Pages 
      

     

    CUSIP No. 28623U101

     

    13G/A Page 4 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    KEVIN TANG

     

    2 Check the Appropriate Box if a Member of a Group* (a) ☐
    (
    b) ☒

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states

     

    Number of
    Shares
    BENEFICIALLY
    Owned by
    Each Reporting
    Person with
    5

    Sole Voting Power

     

    0 

    6

    Shared Voting Power

     

    4,300,454

    7

    Sole Dispositive Power

     

    0 

    8

    Shared Dispositive Power

     

    4,300,454

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,300,454

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.99%

    12

    type of reporting person

     

    IN 

     

     Page 4 of 8 Pages 
      

     

    Item 1(a).Name of Issuer:

     

    Elevation Oncology, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    101 Federal Street, Suite 1900, Boston, MA 02110

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 28623U101

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 4,300,454 shares of the Issuer’s Common Stock, which consists of: (i) 3,667,600 shares of the Issuer’s Common Stock and (ii) 632,854 shares currently issuable upon exercise of Warrants (as defined below).

     

    Tang Capital Partners owns 3,750,000 of the Issuer’s Purchase Warrants (the “Warrants,” as defined in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on June 9, 2023).

     

    Each Warrant is exercisable for one share of the Issuer’s Common Stock. The Warrants are immediately exercisable and expire five years from the date of issuance. Tang Capital Partners may not exercise any portion of the Warrants for shares of Common Stock if, as a result of the exercise, Tang Capital Partners, together with its affiliates and any other person or entity acting as a group, would own more than 9.99% of the Issuer’s outstanding shares of Common Stock after exercise.

     

    The foregoing limitations remain in effect with respect to the Warrants, and, accordingly, only 632,854 shares are currently issuable upon exercise of the Warrants.

     

     Page 5 of 8 Pages 
      

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 4,300,454 shares of the Issuer’s Common Stock, which consists of: (i) 3,667,600 shares of the Issuer’s Common Stock and (ii) 632,854 shares currently issuable upon exercise of Warrants.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 4,300,454 shares of the Issuer's Common Stock, which consists of: (i) 3,667,600 shares of the Issuer's Common Stock and (ii) 632,854 shares currently issuable upon exercise of Warrants.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

    The percentages used herein are based on 43,047,595 shares of Common Stock outstanding, which is comprised of: (i) 42,414,741 shares of Common Stock outstanding as of October 27, 2023, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on November 2, 2023 and (ii) 632,854 shares currently issuable upon exercise of Warrants.

     

    (b)Percent of Class:

     

    Tang Capital Partners 9.99%
    Tang Capital Management 9.99%
    Kevin Tang 9.99%

     

    (c)Number of shares as to which such person has:

     

    (i)      sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)    shared power to vote or to direct the vote:

     

    Tang Capital Partners

    4,300,454 shares

    Tang Capital Management

    4,300,454 shares

    Kevin Tang

    4,300,454 shares

     

    (iii)    sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)   shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners

    4,300,454 shares

    Tang Capital Management

    4,300,454 shares

    Kevin Tang

    4,300,454 shares

     

     Page 6 of 8 Pages 
      

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

      

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 Pages 
      

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date:   February 14, 2024  
         
         
    TANG CAPITAL PARTNERS, LP  
         
    By:   Tang Capital Management, LLC, its General Partner  
         
         
    By:   /s/ Kevin Tang  
       Kevin Tang, Manager  
         
         
    TANG CAPITAL MANAGEMENT, LLC
         
         
    By: /s/ Kevin Tang  
    Kevin Tang, Manager  
         
         
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 Pages

     

     

    Get the next $ELEV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELEV

    DatePrice TargetRatingAnalyst
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    3/21/2025$1.00Outperform → Market Perform
    Leerink Partners
    3/21/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/21/2025$0.70Overweight → Neutral
    Piper Sandler
    1/3/2025Outperform
    William Blair
    5/31/2024$10.00Overweight
    Piper Sandler
    5/14/2024$8.00Overweight
    Stephens
    3/1/2024$7.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $ELEV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

    BOSTON, June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock ("Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (

    6/9/25 8:00:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

    -- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 -- BOSTON, May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2025, and provided recent business updates. "We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, an

    5/15/25 7:30:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

    -- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON, April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, b

    4/25/25 1:00:00 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    SEC Filings

    View All

    SEC Form 15-12G filed by Elevation Oncology Inc.

    15-12G - Elevation Oncology, Inc. (0001783032) (Filer)

    8/4/25 4:34:55 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Elevation Oncology Inc.

    EFFECT - Elevation Oncology, Inc. (0001783032) (Filer)

    7/29/25 12:15:02 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Elevation Oncology Inc.

    EFFECT - Elevation Oncology, Inc. (0001783032) (Filer)

    7/29/25 12:15:05 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevation Oncology downgraded by Stephens with a new price target

    Stephens downgraded Elevation Oncology from Overweight to Equal-Weight and set a new price target of $1.00 from $5.00 previously

    3/24/25 8:34:27 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Elevation Oncology from Outperform to Market Perform and set a new price target of $1.00

    3/21/25 8:03:34 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology downgraded by Citizens JMP

    Citizens JMP downgraded Elevation Oncology from Mkt Outperform to Mkt Perform

    3/21/25 8:03:24 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sandler Alan B.

    4 - Elevation Oncology, Inc. (0001783032) (Issuer)

    7/24/25 4:40:04 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Mootz Darcy

    4 - Elevation Oncology, Inc. (0001783032) (Issuer)

    7/24/25 4:35:04 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Elms Steve

    4 - Elevation Oncology, Inc. (0001783032) (Issuer)

    7/24/25 4:30:06 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

    BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board,

    3/4/24 7:30:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

    BOSTON, Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors. Dr. Mootz is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations to Elevation Oncology's Board of Directors. "We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development str

    1/22/24 7:30:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

    NEW YORK, July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra, M.B.A., as its Chief Executive Officer. Mr. Ferra was previously Interim Chief Executive Officer and Chief Financial Officer. Mr. Ferra will also join the Elevation Oncology Board of Directors. In addition, the Company announced the appointment of Tammy Furlong, M.B.A., C.P.A., as Chief Financial Officer, promoted from her previous role as Vice President of Finance and Accounting

    7/13/23 8:00:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:50:19 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:05:59 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 6:45:37 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Financials

    Live finance-specific insights

    View All

    Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

    -- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30

    8/6/24 7:10:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

    -- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer ---- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia --  -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 ---- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON, Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective ca

    8/6/24 7:00:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

    Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801)Expands pipeline to now include two clinical stage precision oncology candidates for patients with genomically defined solid tumors, including those with Claudin18.2 overexpressionCompany expects to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 (SYSA1801) in 2023Management to host an investor conference call and webcast today at 5:00 p.m. ET NEW YORK, July 28, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, tod

    7/28/22 8:45:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care